{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["32(2)"],"submitter":["Besse B"],"pubmed_abstract":["Early-generation TRK tyrosine kinase inhibitors (TKIs) approved for treating NTRK fusion-positive (NTRK<sup>+</sup>) solid tumors provide clinical benefit; however, resistance emerges. Repotrectinib is a next-generation ROS1/TRK TKI with a compact macrocyclic structure designed to improve durability of response. TRIDENT-1 is a registrational phase 1/2 trial assessing repotrectinib, a next-generation ROS1/TRK TKI, in adults with advanced solid tumors, including NTRK<sup>+</sup> disease. The primary endpoint was confirmed objective response; secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival and safety. Median follow-up ranged between 21.3 months and 25.7 months. In the TKI-naive cohort (n = 51; 95% confidence interval (CI)), the respon"],"journal":["Nature medicine"],"pagination":["682-689"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12920079"],"repository":["biostudies-literature"],"pubmed_title":["Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial."],"pmcid":["PMC12920079"],"pubmed_authors":["Kollengode K","Yang H","Popat S","Calvet CY","Lin JJ","Yang N","Solomon BJ","Springfeld C","Lim DWT","Hong JY","Bazhenova L","Hammell AB","de Langen AJ","Kim DW","Goto K","Nagasaka M","Baik CS","Moreno V","Hervieu A","Wolf J","Drilon A","Besse B","Xu Y","Yuan Y"],"additional_accession":[]},"is_claimable":false,"name":"Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial.","description":"Early-generation TRK tyrosine kinase inhibitors (TKIs) approved for treating NTRK fusion-positive (NTRK<sup>+</sup>) solid tumors provide clinical benefit; however, resistance emerges. Repotrectinib is a next-generation ROS1/TRK TKI with a compact macrocyclic structure designed to improve durability of response. TRIDENT-1 is a registrational phase 1/2 trial assessing repotrectinib, a next-generation ROS1/TRK TKI, in adults with advanced solid tumors, including NTRK<sup>+</sup> disease. The primary endpoint was confirmed objective response; secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival and safety. Median follow-up ranged between 21.3 months and 25.7 months. In the TKI-naive cohort (n = 51; 95% confidence interval (CI)), the respon","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T15:11:00.988Z","creation":"2026-07-09T11:03:02.069Z"},"accession":"S-EPMC12920079","cross_references":{"pubmed":["41639379"],"doi":["10.1038/s41591-025-04079-7"]}}